GSK wins right to appeal against NICE Benlysta guidance
This article was originally published in Scrip
Executive Summary
NICE, the UK National Institute for Health and Clinical Excellence will take a second look at its final appraisal determination rejecting GlaxoSmithKline's Lupus treatment Benylsta (belimumab) after an appeal against the guidance was upheld.